Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy of Sciences (CAS) in 2016, reportedly raised around RMB 500 million (USD 71.9 million) in a Series D financing round. The firm previously raised RMB 300 million (USD 43.1 million) via a Series C funding held in August last year. The latest round was led by SDIC Venture Capital and China Venture Capital, which included contributions from Taiping Medical and Health Fund, Jianxing Medical Health Industry Equity Investment, CICC Capital, and Beijing FOF Capital. Proceeds will be used to ramp up the CRO service platform, cell and gene therapy technology platform capabilities, research facilities construction, and one-stop CRO services.
Company Background and Services
SAFE, with branches in Shenzhen, Chengdu, Suzhou, and Shenyang in China, as well as the United States, boasts a business footprint covering pharmaceutical research and development (R&D) consulting, regulatory affairs relating to the National Medical Products Administration (NMPA) and US FDA, pharmaceutical preparations, pharmacological effects, model animals, drug metabolism analysis, non-clinical safety evaluation, biological sample analysis, Phase I clinical studies, pharmacovigilance, and other professional technical services, as well as innovative drug incubation investment. Offerings cover vaccines, nucleic acid drugs, antibody-drug conjugates (ADC), gene and cell therapies, polyclonal antibodies, oncolytic viruses, and more.-Fineline Info & Tech
